Effect of Three Decades of Screening Mammography on Breast-cancer Incidence
Overview
Authors
Affiliations
Background: To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage.
Methods: We used Surveillance, Epidemiology, and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older.
Results: The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year, from 112 to 234 cases per 100,000 women--an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased by 8%, from 102 to 94 cases per 100,000 women--an absolute decrease of 8 cases per 100,000 women. With the assumption of a constant underlying disease burden, only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease. After excluding the transient excess incidence associated with hormone-replacement therapy and adjusting for trends in the incidence of breast cancer among women younger than 40 years of age, we estimated that breast cancer was overdiagnosed (i.e., tumors were detected on screening that would never have led to clinical symptoms) in 1.3 million U.S. women in the past 30 years. We estimated that in 2008, breast cancer was overdiagnosed in more than 70,000 women; this accounted for 31% of all breast cancers diagnosed.
Conclusions: Despite substantial increases in the number of cases of early-stage breast cancer detected, screening mammography has only marginally reduced the rate at which women present with advanced cancer. Although it is not certain which women have been affected, the imbalance suggests that there is substantial overdiagnosis, accounting for nearly a third of all newly diagnosed breast cancers, and that screening is having, at best, only a small effect on the rate of death from breast cancer.
From morphology to single-cell molecules: high-resolution 3D histology in biomedicine.
Xu X, Su J, Zhu R, Li K, Zhao X, Fan J Mol Cancer. 2025; 24(1):63.
PMID: 40033282 PMC: 11874780. DOI: 10.1186/s12943-025-02240-x.
Lin Y, Zhang Q, Chen H, Liu S, Peng K, Wang X BMC Med. 2025; 23(1):97.
PMID: 39984977 PMC: 11846373. DOI: 10.1186/s12916-025-03887-5.
Incidence trends of ductal carcinoma in situ in New Zealand women between 1999 and 2022.
Chen Q, Elwood M, Campbell I, Cavadino A, Aye P, Tin Tin S Breast Cancer Res Treat. 2025; .
PMID: 39856462 DOI: 10.1007/s10549-024-07582-6.
The Microenvironment in DCIS and Its Role in Disease Progression.
Roozitalab M, Prekete N, Allen M, Grose R, Jones J Adv Exp Med Biol. 2025; 1464():211-235.
PMID: 39821028 DOI: 10.1007/978-3-031-70875-6_12.
Daniels J, Amunyela O, Nyantakyi A, Ayabilah E, Tackie J, Kyei K Ecancermedicalscience. 2025; 18():1805.
PMID: 39816394 PMC: 11735141. DOI: 10.3332/ecancer.2024.1805.